Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people - Seite 2

Another important biomarker, Elecsys cTnT-hs, now provides healthcare professionals with data to help predict heart attack risk and mortality in non-cardiac surgery patients. Every year, over 200 million adults undergo major non-cardiac surgery with 10 million suffering from major adverse cardiac events (MACE) that could be prevented through early and accurate diagnosis¹².

Both Elecsys NT-proBNP and Elecsys cTnT-hs can be run on all cobas e analysers. They are among the first products certified under the new European In Vitro Diagnostics Regulation (IVDR) and available as of today in countries accepting CE mark. Availability in other countries is subject to local registration processes and timelines.

About Elecsys NT-proBNP
Tests for NT-proBNP, a cardiac hormone that is released into the blood when the heart wall is stretched, are developed and marketed by Roche. NT-proBNP is an objective marker for the aid in diagnosis in individuals suspected of having congestive heart failure and detection of mild forms of cardiac dysfunction. This assay is further indicated for the risk stratification of patients with acute coronary syndrome and congestive heart failure, and it can also be used for monitoring the treatment in patients with left ventricular dysfunction.

Added intended uses for Elecsys NT-proBNP
(1) Type-2 diabetes and heart failure
463 million people suffer from type-2 diabetes worldwide⁴ and are at higher risk of developing cardiovascular disease. The new intended use of Elecsys NT-proBNP provides healthcare professionals with a precise biomarker that supports them to identify patients with high cardiovascular risk. This means that effective drug treatment can be started early so that cardioprotective treatment can be optimized. In PONTIAC-I it was shown that 65% of hospitalisations or death could be prevented⁸.

(2) Atrial fibrillation
More than 37 million people suffer from Atrial Fibrillation (AF) and 25% of people over 40 years old develop AF in their lifetime. More than 450 million people aged 70 or above are considered high risk for this disease. Patients with AF are exposed to a fivefold risk of stroke¹³ and therefore brain damage or death¹⁴. One of the key elements in reducing stroke is early detection of people at risk of Atrial Fibrillation by better identification methods. Our second launched intended use for Elecsys NT-proBNP provides healthcare professionals with a biomarker based solution that identifies people at risk and, in combination with a single lead (or higher) ECG, can aid successful diagnosis so therapy can be started.